Journal of Developmental Medicine(Electronic Version)  2022, Vol. 10 Issue (5): 353-359 DOI: 10.3969/j.issn.2095-5340.2022.05.005 |
|
|
|
|
|
|
| Effect and safety evaluation of metabolic indexes in postmenopausal women with long-term use of tibolone |
| Xue Wanjun, Guo Xuetao, Yan Yaru, et al
|
1. The First Clinical Medical College,Shanxi Medical University, Shanxi, Taiyuan 030001, China; 2. Department of Gynecology, The First Hospitalof Shanxi Medical University, Shanxi, Taiyuan 030001, China
|
|
|
|
Abstract 【Abstract】 Objective To investigate the effect and the safety on glucose and lipid metabolism inpostmenopausal women with long-term use of tibolone. Method From November 2011 to December
2021, 68 postmenopausal women who had undergone menopause hormone therapy (MHT) in the First
Hospital of Shanxi Medical University by retrospective analysis , who oral tibolone 1.25 mg/d. Follow-up to
12, 24 and 36 months, the number of cases were 68, 50 and 32. Body mass index (BMI) ,waist circumference,systolic pressure, diastolic blood pressure, modified Kupperman score, fasting blood glucose, total cholesterol,triglycerides, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C),liver and kidney function values, bone mineral density were collected. t-test and rank sum test were used forstatistical analysis. Result The baseline value of the modified Kupperman score was (20.0±8.9), whichwas significantly decreased to (7.2±5.5) after 3 months of tibolone treatment, the difference was statisticallysignificant (t=11.967, P<0.001). There was no statistical significance in BMI, waist circumference, systolicpressure, diastolic blood pressure, during the observation period (P>0.05). After 12 months of treatment, TCand TG were [4.6 (4.0, 5.1) vs 0.9 (0.7, 1.1) mmol/L], respectively; after 24 months of treatment, TC and TGwere [4.6 (3.9, 5.0) vs 0.8 (0.6, 1.2) mmol/L], respectively, which were lower than those before treatment[5.0 (4.4, 5.4), 1.1 (0.8, 1.6) vs 4.9 (4.2, 5.2), 1.0 (0.8, 1.6) mmol/L, all P<0.05]. HDL-C at 12, 24 and 36months of treatment were [1.3 (1.1, 1.5), 1.3 (1.1, 1.6), 1.2 (1.0, 1.6) mmol/L], respectively, which werelower than those before treatment [1.4 (1.2, 1.8), 1.6 (1.3, 1.9), 1.5 (1.3, 1.8) mmol/L, all P<0.01]. There wasno statistical significance in LDL-C and fasting blood glucose decreased in different treatment time periods(P>0.05); After 36 months of treatment, Urea was lower than before treatment [4.9 (4.6, 7.8) vs 4.6 (3.9,4.9) mmol/L], the difference was statistically significant (P<0.05). After 12 months of treatment , CRE washigher than before treatment [57.0 (26.4, 66.6) vs 68.0 (59.0, 78.5) μmol/L], the difference was statisticallysignificant (P<0.05), but within the normal range. There was no significant change in the bone mineraldensity of the left hip and right hip at different time periods (P>0.05); the bone mineral density of the lumbarspine were [(0.934±0.104), (0.936±0.121) and (0.986±0.156) g/cm2], higher than those before treatment
[(0.911±0.112), (0.905±0.135) and (0.919±0.171) g/cm2, P<0.05]. Conclusion After 3 months of
tibolone treatment, menopausal symptoms are significantly improved or even disappeared. It has little effecton body weight, body posture and blood pressure with longest medication for 36 months, it can effectivelyreduce the levels of TC and TG, while reducing the level of HDL-C, it has no effect on the liver and kidneyfunctions; the bone density of the lumbar spine is improved, and had no effect on the bone mineral density of the hip.
|
|
Received: 27 January 2022
Published: 30 September 2022
|
|
|
|
|
|
